

---

---

# CHINESE JOURNAL OF NEPHROLOGY

Monthly    Established in March 1985    Volume 42, Number 2    February 15, 2026

---

## Responsible Institution

China Association for Science  
and Technology

## Sponsor

Chinese Medical Association  
42 Dongsi Xidajie, Beijing 100710, China

## Editing

Editorial Board of Chinese Journal of  
Nephrology  
58 Zhongshan Road II, Guangzhou 510080, China  
Tel: 0086-20-87331532  
Email: emaszb@cmaph.org  
http://www.medjournals.cn  
http://www.cjn.org.cn

## Editor-in-Chief

Yu Xueqing (余学清)

## Managing Director

Wang Xin (王欣)

## Publishing

Chinese Medical Journals  
Publishing House Co., Ltd.  
42 Dongsi Xidajie, Beijing 100710, China  
Tel(Fax): 0086-10-51322059  
Email: office@cmaph.org

## Printing

Guangzhou BaoCheng Printing Co., Ltd.

## Overseas Distributor

China International Book  
Trading Corporation  
P. O. Box 399, Beijing 100048, China  
Code No. M86

## Mail-Order

Editorial Board of Chinese  
Journal of Nephrology  
58 Zhongshan Road II, Guangzhou 510080, China  
Tel: 0086-20-87331532  
Email: emaszb@cmaph.org

## CSSN

ISSN 1001-7097  
CN 44-1217/R

## Copyright © 2026 by the Chinese Medical Association

No content published by the journals of Chinese  
Medical Association may be reproduced or  
abridged without authorization. Please do not use  
or copy the layout and design of the journals  
without permission.

All articles published represent the opinions of  
the authors, and do not reflect the official policy  
of the Chinese Medical Association or the  
Editorial Board, unless this is clearly specified.

## CONTENTS IN BRIEF

### Clinical Study

#### Efficacy and safety comparison of erythropoietin and roxadustat in the treatment of anemia in peri-dialysis patients with chronic kidney disease: a multicenter real-world retrospective study

..... 81

*Wang Lihua, Cao Yueqi, Yuan Weijie, Hao Chuanming, Yao Li,  
Yu Pei, Mei Changlin*

#### Short-term effect of sucroferriic oxyhydroxide on phosphorus reduction in end-stage renal disease patients with hyperphosphatemia

..... 90

*Ai Yuanyuan, Bao Sizeng, Bian Xueyan*

#### Comparison of the application of upper arm tapered arteriovenous graft and standard arteriovenous graft in patients with end-stage renal disease

..... 95

*Zheng Xin, Zhang Lihong, Ren Shufeng, Cui Rui, Zhan Shen, Wang Yuzhu*

#### Exploration of related factors of early-onset acute kidney disease in patients with idiopathic membranous nephropathy and creation of a risk scoring system

..... 102

*Yang Lei, Wang Guoqin, Ye Nan, Xu Xiaoyi, Cheng Wenrong,  
Wang Yanyan, Kong Lingqiang, Cheng Hong*

### Basic Study

#### Methyltransferase-like 3 alleviates vascular calcification in chronic kidney disease rats by inhibiting the m6A methylation modification of histone deacetylase 1

..... 110

*Wang Chunli, Chen Ruman, Wang Cuijuan, Bai Yafei*

### Case Report

#### Exercise-induced acute kidney injury without renal hypuricemia: a case report

..... 117

*Jiao Chenfeng, Zhao Liang, Jiang Ling, Fan Wenjing, Zhang Jiong*

|  |     |
|--|-----|
| <b>Rituximab-induced interstitial lung disease during treatment of membranous nephropathy: a case report</b>                     | 120 |
| <i>Wang Jingnan, Jiang Lanping, Chen Xionghui, Li Zhijian, Chen Wei, Wang Xin</i>  |     |
| <b>Membranous nephropathy complicated with Kaposi sarcoma: a case report with a literature review</b>                            | 123 |
| <i>Liu Weilin, Gong Song, Qin Lingzhi, Zhou Sheng, Xu Gang, Dong Lei</i>   |     |
| <b>VEXAS syndrome accompanied with interstitial nephritis: a case report and literature review</b>                               | 128 |
| <i>Teng Fei, Xing Haiping, Shou Yiran, Ye Wei, Wen Yubing, Chen Gang, Li Xuemei</i>  |     |
| <b>Autosomal dominant tubulointerstitial kidney disease caused by a pathogenic variant in <i>SEC61A1</i> gene: a case report</b> | 133 |
| <i>Cheng Yun, Zhu Guoqin, Yao Yao, Liu Xunwei, Li Guomin</i>   |     |

## Experience Exchange

|  |     |
|--|-----|
| <b>Clinical efficacy and safety of eculizumab in patients with atypical hemolytic uremic syndrome: a retrospective analysis based on real-world data</b> | 138 |
| <i>Zhang Yanyan, Wang Wei, Li Guisen, Chen Shasha</i>  |     |

## Review

|  |     |
|--|-----|
| <b>Research advances on the effects and related mechanisms of sodium-glucose transporter 2 inhibitors on acute kidney injury</b>                       | 144 |
| <i>Wang Xueqi, Ma Yizhao, Cai Guangyan</i>   |     |
| <b>Research progress of antiplatelet drugs used in the prevention and treatment of cardiovascular diseases in patients with chronic kidney disease</b> | 150 |
| <i>Nie Zhaoying, Ding Xiaoqiang, Yu Xiaofang</i>   |     |
| <b>Pharmacokinetic characteristics and their clinical applications in peritoneal dialysis patients</b>   | 156 |
| <i>Xu Chenhong, Xiang Qian, Dong Jie</i>   |     |